These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 16395110)

  • 1. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.
    de Greeff SC; de Melker HE; Spanjaard L; Schouls LM; van Derende A
    Pediatr Infect Dis J; 2006 Jan; 25(1):79-80. PubMed ID: 16395110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.
    Kaaijk P; van der Ende A; Berbers G; van den Dobbelsteen GP; Rots NY
    BMC Infect Dis; 2012 Feb; 12():35. PubMed ID: 22316426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of systematic vaccination with the antimeningococcal C conjugated vaccine in a health area in Andalusia].
    Cruz Rojo C; García Gil C; Nieto Vera J; Monroy Morcillo A
    Rev Esp Salud Publica; 2005; 79(6):655-63. PubMed ID: 16457057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
    Pace D; Pollard AJ
    Arch Dis Child; 2007 Oct; 92(10):909-15. PubMed ID: 17895339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal disease: the advances and challenges of meningococcal disease prevention.
    Yogev R; Tan T
    Hum Vaccin; 2011 Aug; 7(8):828-37. PubMed ID: 21832882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil.
    Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL;
    Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-meningococcal vaccines: diversity of vaccination policies and recommendations].
    Gendrel D
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S70-6. PubMed ID: 22883370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
    Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA
    Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.
    Lawrence GL; Wang H; Lahra M; Booy R; McINTYRE PB
    Epidemiol Infect; 2016 Aug; 144(11):2382-91. PubMed ID: 27094814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 20. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.
    Rose WE
    J Am Pharm Assoc (2003); 2014; 54(2):198-201. PubMed ID: 24632933
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.